CG Oncology Q3 net loss $43.8M ($0.57/share); initiates BLA for cretostimogene

CG Oncology, Inc.

2025-Q3 EPS reported -$1.57 revenue$1,718,000

Net loss of $43.8M ($0.57 per share) for Q3 2025 vs $20.4M ($0.30) in Q3 2024.
Cash, cash equivalents and marketable securities $680.3M, sufficient to fund operations into H1 2028.
Initiated rolling BLA submission to FDA for cretostimogene monotherapy in HR BCG-unresponsive NMIBC.
R&D expenses $27.9M (up 42% YoY), G&A $23.3M (up 168% YoY) driven by clinical trials and headcount.
Completed enrollment of Phase 3 PIVOT-006 trial in IR NMIBC 10 months ahead of schedule.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.